NCT05717803 is a Phase 3 clinical trial of Segmentectomy in Segmentectomy, sponsored by Fudan University.

Who is sponsoring NCT05717803?

NCT05717803 is sponsored by Fudan University.

What drugs are being tested in NCT05717803?

Interventions in NCT05717803: Segmentectomy.

What condition does NCT05717803 study?

NCT05717803 studies Segmentectomy, Lung Adenocarcinoma.

Is NCT05717803 still recruiting?

NCT05717803 is currently recruiting now. Last updated 3 June 2024.

Last reviewed 2024-06-03 · How we verify

NCT05717803

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)

Recruiting now Phase 3 Last updated 3 June 2024

What this trial tests

Phase 3 trial testing Segmentectomy in Segmentectomy in 307 participants. Currently enrolling.

Timeline

15 February 2023

Primary endpoint
31 December 2028

31 December 2029

Quick facts

Lead sponsor	Fudan University
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	307
Start date	15 February 2023
Primary completion	31 December 2028
Estimated completion	31 December 2029
Sites	1 location across China

Drugs / interventions tested

Segmentectomy

Conditions studied

Segmentectomy — all drugs for Segmentectomy →
Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →

Sponsor

Fudan University

Who can join

Adults 18 to 80, any sex, with Segmentectomy or Lung Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: * The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm; * The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Segmentectomy for ground glass-dominant invasive lung cancer with tumour diameter of 2-3 cm: protocol for a single-arm, multicentre, phase III trial (ECTOP1012).
Chen S, Huang Q, Fu F, Wang Z, et al · · 2024 · cited 1× · PMID 38960464 · DOI 10.1136/bmjopen-2024-087088
Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches.
Ohtaki Y, Aokage K, Miyoshi T, Tane K, et al · · 2026 · PMID 41642077 · DOI 10.1093/jjco/hyag013

Verify or expand the search:

Other trials of Segmentectomy

Trials testing the same drug.

NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06496659 — Segmentectomy After Induction Therapy (SAINT) · NA · recruiting
NCT06634966 — Segmentectomy for Solid-dominant Lung Cancer · Phase 3 · recruiting
NCT04944563 — Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field · NA · recruiting
NCT05695404 — Contribution of 3D Printing in Anatomical Lung Segmentectomies. · completed

Other recruiting trials for Segmentectomy

Currently open trials in the same condition.

NCT06516198 — Auricular Acupressure in Prehabilitation · NA · recruiting
NCT06496659 — Segmentectomy After Induction Therapy (SAINT) · NA · recruiting
NCT06634966 — Segmentectomy for Solid-dominant Lung Cancer · Phase 3 · recruiting
NCT05525923 — Personalized Postoperative Pain Management Following Thoracic Surgery in Adults · recruiting
NCT05453721 — Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Metho · NA · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05717803 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 3 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05717803.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing